Amid the all the numbers in Pfizer's ($PFE) third-quarter earnings announcement, the drugmaker disclosed one particularly newsworthy figure: A $491 million charge for a Rapamune marketing settlement. As Dow Jones first reported, the company made a deal with the U.S. Justice Department to resolve the longstanding probe, which Pfizer inherited when it bought Wyeth in 2009.
The drugmaker had faced allegations that Wyeth pushed Rapamune for unapproved uses--and that it used kickbacks to persuade doctors. In 2010, the feds joined a whistleblower case, filed by two former Wyeth salespeople, claiming that the company not only touted the organ-transplant drug for off-label use, but specifically targeted hospitals that mostly treated African-Americans, despite higher risks in those patients.
Read more: Pfizer discloses $491M charge for Rapamune marketing settlement - FiercePharma http://www.fiercepharma.com/story/pfizer-discloses-491m-charge-rapamune-marke...
Subscribe: http://www.fiercepharma.com/signup?sourceform=Viral-Tynt-FiercePharma-FierceP...
No comments:
Post a Comment